On Our Radar

On Our Radar

It’s not all about oncology (Part 3 - Hemophilia).

Following on BioMarin’s setbacks with a hemophilia gene therapy earlier this year, Novo invests in a spin out with experienced, home grown drug hunters and a bispecific antibody platform that produced spectacular results in Multiple Myeloma through Darzalex. 


要查看或添加评论,请登录

Jonathan Usuka的更多文章

社区洞察

其他会员也浏览了